Read all our latest news about Parkinson's research.
GDNF trial complete and results are on the way
The groundbreaking clinical trial of GDNF, a potential treatment for Parkinson's, is now complete. Analysis of the results is now well underway and is expected to be published in the summer.
Repurposing drugs to slow dementia
New research shows promise for repurposed drugs that slow dementia.
Reprogramming brain cells to reverse Parkinson’s
New research published in Nature Biotechnology shows that it may be possible to reprogramme cells inside the brain to reverse the symptoms of Parkinson's.
Hepatitis infection linked to Parkinson’s risk
Research suggests there may be a link between hepatitis infection and an increased risk of developing Parkinson's.
Welcome to our new Deputy Director of Research
We’re excited to announce that Professor David Dexter has joined us as our new Deputy Director of Research.
Virtual company to create new Parkinson’s treatments
Parkinson's UK and the University of Sheffield have launched a new £1million virtual biotech company, Keapstone Therapeutics, to combine world-leading research from the University with funding and expertise from the charity to develop new treatments.
Phase II clinical trial of cancer drug announced
US researchers have announced the launch of a Phase II clinical trial of the cancer drug nilotinib in people with Parkinson’s.
Positive results from trial of inhalable levodopa
Results from a clinical trial suggest an inhalable form of levodopa could help people with Parkinson's who experience 'off periods'.
Researchers develop test that detects parkinsonisms
Researchers have discovered a potential way to tell the difference between people with Parkinson's and those with parkinsonisms using a simple blood test.
New route to repurposed drugs for Parkinson's
Researchers in Oxford have developed a unique way to identify existing drugs that could potentially be repurposed for treating Parkinson’s.